Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
about
Rimonabant for overweight or obesityPharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicitySmoking and suicide: a brief overviewHypertriglyceridemia: its etiology, effects and treatmentGut hormones and the regulation of energy homeostasisNew developments in the pharmacotherapy of cocaine abuseMETABOLIC EFFECTS OF MARIJUANA USE AMONG BLACKS.Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsA possible role for the endocannabinoid system in the neurobiology of depressionCannabinoid receptors in acute and chronic complications of atherosclerosis.Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity.Cannabidiol arrests onset of autoimmune diabetes in NOD miceRimonabant for treating tobacco dependence.The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.Genetic forms of the cardiometabolic syndrome: what can they tell the clinician?Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis.CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.Pharmacotherapy for smoking cessation.Rimonabant inhibits TNF-α-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway.Platelet activation in obesity and metabolic syndrome.A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.Recurrent STEMI Precipitated by Marijuana Use: Case Report and Literature Review
P2860
Q24244078-35B5A3BF-A770-43CB-BB43-656D84DE104EQ24648835-68A521B9-B2F6-47C8-A759-A54F587C3FBBQ24655785-02788E6A-28B6-436A-ADF1-28AD443559A8Q24672914-3EC9AB04-FEDC-4FB1-8D1A-1BB73C78EFECQ28278826-53E06A3B-BEEC-4EF9-A3C7-3ACA0E758901Q28302782-775B2696-D9A2-44B5-976F-F1A2CF037AD1Q35911477-A1EA1A4E-0A20-400D-A951-BC52C8BB5EBCQ36052772-9F8359B0-6FF8-4AC1-892D-1F8C9B372FD3Q36316074-7E27935A-476E-4176-85DC-DB5EC211EE3BQ36416368-52E80E89-CDD2-48B6-89B2-F90E84FED6A9Q36431832-71240E53-724B-4E3D-9DE1-06021A98C004Q36501954-2A5A2DF0-D457-4FAB-9C68-7D871A8993D5Q36541435-C3CBBEB3-B441-4BC3-9637-B7C3BD530726Q36773310-432931A8-4EDE-45A0-8CFB-B99B13CD9CEAQ36904431-1959C75B-22A2-447B-9719-56397F4EEBACQ36966063-FB8B31EE-14FF-4DD3-8805-4D866AFC08A9Q37091495-1A2E931D-F5FE-4778-971A-5661D7EC1068Q37143614-90FF941D-DD89-4B5D-BD50-95703EA80E47Q37362638-1581519D-963B-48C6-BDF7-919127430789Q37729882-DC7C6155-5F48-41BA-BC54-7A87C62AFC20Q37932076-6559B9C0-992D-4A3A-9DAC-EBCA8B18D440Q38544824-EDA1546C-7EF2-4A84-AA05-5C82E42D7082Q46769723-9616C08E-6420-4A61-829B-B2ACCA83A420Q57193204-38190B67-DD5B-45D5-9707-E649D52C6779
P2860
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Rimonabant: a cannabinoid rece ...... cardiometabolic risk factors.
@ast
Rimonabant: a cannabinoid rece ...... cardiometabolic risk factors.
@en
type
label
Rimonabant: a cannabinoid rece ...... cardiometabolic risk factors.
@ast
Rimonabant: a cannabinoid rece ...... cardiometabolic risk factors.
@en
prefLabel
Rimonabant: a cannabinoid rece ...... cardiometabolic risk factors.
@ast
Rimonabant: a cannabinoid rece ...... cardiometabolic risk factors.
@en
P921
P1476
Rimonabant: a cannabinoid rece ...... cardiometabolic risk factors.
@en
P2093
Christopher P Cannon
Eli V Gelfand
P304
P356
10.1016/J.JACC.2005.12.067
P407
P577
2006-04-24T00:00:00Z